We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Antibody Prevents Death of Neurons after Injury

By HospiMedica staff writers
Posted on 01 Apr 2004
A study has shown that the infusion of an antibody to the proNGF protein in an animal model can save injured neurons from death, suggesting a therapy for brain and spinal cord damage. More...
The study was published in the March 19, 2004, online Proceedings of the [U.S.] National Academy of Sciences.

Dead or dying nerve cells caused by stroke or neurodegenerative diseases such as Alzheimer's are known to trigger cell death in their healthy neighbors. The resulting cascade of cell deaths is often more devastating to the brain and spinal cord than the original injury, according to the researchers. They used an antibody to the proNGF protein, secreted by cells in an injured brain, to prevent its interaction with another protein, p75, found on the surface of injured neurons. By doing so, they were able to prevent the death of cortical neurons in mice and rats. The treatment increased nerve cell survival by more than 90%, compared to 61-66% in untreated animals.

Although the antibody used in the study is not appropriate for the treatment of humans, the study shows that proNGF is a viable target for discovering molecules that can be used to block the protein in patients. ProNGF is an unprocessed form of NGF, nerve growth factor.

"If you could identify a compound that could pass the blood-brain barrier and impair the binding of proneurotrophin to cell receptors, then it could be a potential drug that could be tested in animals and eventually patients,” noted Dr. Barbara Hempstead, professor of cardiovascular medicine at Weill Cornell Medical College (New York, NY, USA; www.med.cornell.edu) and a co-author of the study. Researchers at the University of Texas Southwestern Medical Center (USA), Ohio State University (USA), and the University of Saarland (Germany) also contributed to the study.




Related Links:
Weill Cornell Medical College

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Glucose Meter
StatStrip®
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.